[Response evaluation in nuclear medicine : Criteria, results and pitfalls].

about

[Light at the end of the tunnel].

P2860

Q49921360-745518A8-2284-4C35-BB29-41D09C67AD34

P2860

[Response evaluation in nuclear medicine : Criteria, results and pitfalls].

Item

http://www.wikidata.org/entity/Q50218104

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

[Response evaluation in nuclear medicine : Criteria, results and pitfalls].

@en

[Response evaluation in nuclear medicine : Criteria, results and pitfalls].

@nl

type

Item

label

[Response evaluation in nuclear medicine : Criteria, results and pitfalls].

@en

[Response evaluation in nuclear medicine : Criteria, results and pitfalls].

@nl

prefLabel

[Response evaluation in nuclear medicine : Criteria, results and pitfalls].

@en

[Response evaluation in nuclear medicine : Criteria, results and pitfalls].

@nl

P1476

[Response evaluation in nuclear medicine : Criteria, results and pitfalls].

@en

P2093

C Sachpekidis

http://www.w3.org/2001/XMLSchema#string

J Hoffend

http://www.w3.org/2001/XMLSchema#string

P2860

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

Differences in the biologic activity of 2 novel MEK inhibitors revealed by 18F-FDG PET: analysis of imaging data from 2 phase I trials.

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.

From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.

Pseudoprogression and Immune-Related Response in Solid Tumors

Correlation between early 18F-FDG PET/CT response to BRAF and MEK inhibition and survival in patients with BRAF-mutant metastatic melanoma

Fractal and multifractal analysis of PET/CT images of metastatic melanoma before and after treatment with ipilimumab.

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.

Management of immune-related adverse events and kinetics of response with ipilimumab.

FDG PET/CT in infection and inflammation--current and emerging clinical applications.

P2888

s00117-017-0295-y

P304

834-839

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00117-017-0295-Y

http://www.w3.org/2001/XMLSchema#string

P407

Af-Jarmal

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Antonia Dimitrakopoulou-Strauss

P577

2017-09-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28875325

http://www.w3.org/2001/XMLSchema#string

[Response evaluation in nuclear medicine : Criteria, results and pitfalls].

about

P2860

P2860

[Response evaluation in nuclear medicine : Criteria, results and pitfalls].

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P698